Catalyst Funds Management’s Alto Neuroscience ANRO Stock Holding History

Catalyst Funds Management’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,400	Closed	-$256K	–	921
2026 Q1	$256K	Buy	+11,400	New	+$211K	0.04%	402

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Catalyst Funds Management's ANRO Position: Q2 2026 in Review

Catalyst Funds Management sold out of Alto Neuroscience (ANRO) in Q2 2026, closing a stake of 11,400 shares — an estimated $256K sold.

Catalyst Funds Management first reported a position in ANRO in Q1 2026 and held it in 1 quarter. The position peaked at $256K in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Catalyst Funds Management reported no remaining Alto Neuroscience position as of Q2 2026 after selling out during the quarter.
Catalyst Funds Management sold 11,400 Alto Neuroscience shares in Q2 2026, an estimated $256K.
Catalyst Funds Management first reported a position in Alto Neuroscience in Q1 2026 and held it in 1 quarter.
Catalyst Funds Management's Alto Neuroscience position peaked at $256K in Q1 2026.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.